Reference

1. ^Sharples, C. G.; Kaiser, P.; Soliakov; Marks; Collins; Washburn; Wright; Spencer; Gallagher (2000). „UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes”.Journal of Neuroscience.20 (8): 2783—2791.PMID 10751429. 
2. ^Cao, Y.; Surowy, C.; Puttfarcken, P. (2005).„Nicotinic acetylcholine receptor-mediated 3Hdopamine release from hippocampus”.The Journal of Pharmacology and Experimental Therapeutics.312 (3): 1298—1304.PMID 15542623.doi:10.1124/jpet.104.076794. 
3. ^Gohlke, H.; Gündisch; Schwarz; Seitz; Tilotta; Wegge (2002). „Synthesis and nicotinic binding studies on enantiopure diazine analogues of the novel (2-chloro-5-pyridyl)-9-azabicyclo4.2.1non-2-ene UB-165”.Journal of Medicinal Chemistry.45 (5): 1064—1072.PMID 11855986.doi:10.1021/jm010936y. 
4. ^Sharples, C. G.; Karig; Simpson; Spencer; Wright; Millar; Wonnacott; Gallagher (2002). „Synthesis and pharmacological characterization of novel analogues of the nicotinic acetylcholine receptor agonist (+/-)-UB-165”.Journal of Medicinal Chemistry.45 (15): 3235—3245.PMID 12109907.doi:10.1021/jm020814l. 
5. ^Sutherland, A.; Gallagher, T.; Sharples, C.; Wonnacott, S. (2003). „Synthesis of two fluoro analogues of the nicotinic acetylcholine receptor agonist UB-165”.The Journal of Organic Chemistry.68 (6): 2475—2478.PMID 12636420.doi:10.1021/jo026698b. 
6. ^Karig, G.; Large; Sharples; Sutherland; Gallagher; Wonnacott (2003). „Synthesis and nicotinic binding of novel phenyl derivatives of UB-165. Identifying factors associated with alpha7 selectivity”.Bioorganic & Medicinal Chemistry Letters.13 (17): 2825—2828.PMID 14611837.doi:10.1016/S0960-894X(03)00594-8. 

Spoljašnje veze